Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V5LJ
|
||||
| Former ID |
DIB016512
|
||||
| Drug Name |
JNJ-10329670
|
||||
| Synonyms |
Cathepsin S inhibitors (autoimmune disease); JNJ-10329670; Cathepsin S inhibitors (autoimmune disease), J&J PRD; Cathepsin S inhibitors (autoimmune disease), Johnson & Johnson
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Investigative | [1] | ||
| Company |
Johnson & Johnson Pharmaceutical Research & Development LLC
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C30H34ClF3N6O3S
|
||||
| Canonical SMILES |
C1CCCN1C(=O)CSc1c(C(F)(F)F)ccc(c1)c1c2CN(CCc2n(CC(CN2CC<br />C(CC2)C)O)n1)C(=O)C
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cathepsin S | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Lysosome | ||||
| Phagosome | |||||
| Antigen processing and presentation | |||||
| Tuberculosis | |||||
| NetPath Pathway | Leptin Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| Reactome | Endosomal/Vacuolar pathway | ||||
| Degradation of the extracellular matrix | |||||
| Trafficking and processing of endosomal TLR | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | Class I MHC mediated antigen processing & presentation | ||||
| Trafficking and processing of endosomal TLR | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.